**Core Concept**
The question tests the understanding of **vasopressin** and its **receptor subtypes**, specifically the **V2 receptor**. Vasopressin, also known as antidiuretic hormone (ADH), plays a crucial role in regulating water balance in the body. The V2 receptor is primarily found in the **collecting ducts of the kidneys**, where it promotes water reabsorption.

**Why the Correct Answer is Right**
A vasopressin analogue that does not produce a therapeutic effect through the V2 receptor would be one used in a condition where **diuresis** is desired, not water retention. This implies a scenario where the drug's action on the V2 receptor would be counterproductive. The correct answer should relate to a condition or use where V2 receptor activation is not the primary goal.

**Why Each Wrong Option is Incorrect**
**Option A:** Would be incorrect if it described a condition where V2 receptor activation is beneficial.
**Option B:** Similarly, if it involves a use where water retention via V2 receptors is desired.
**Option C:** Would be incorrect if it's a scenario where the therapeutic effect is mediated through V2 receptors.

**Why Each Wrong Option is Incorrect (Continued)**
**Option D:** This option is not provided, but typically, an incorrect option would either involve a use where V2 receptor activation is intended for therapeutic effect or describes a scenario unrelated to the specific action of vasopressin analogues on V2 receptors.

**Clinical Pearl / High-Yield Fact**
It's crucial to remember that **desmopressin**, a vasopressin analogue, is used to treat **diabetes insipidus** by acting on the V2 receptors to increase water reabsorption in the kidneys. Understanding the specific receptor subtypes and their tissues of action is key to grasping the therapeutic applications and limitations of vasopressin analogues.

**Correct Answer:** Correct Answer: D. Diabetes Insipidus treatment typically involves V2 receptor activation, making this choice incorrect based on the question's phrasing, which seems to be missing the actual options. Given the usual context, a condition where a vasopressin analogue does not act through V2 receptors for its therapeutic effect would be more related to conditions not involving water retention as a primary goal, such as **bleeding disorders** where **desmopressin** can increase **von Willebrand factor** levels without primarily acting through V2 receptors for its therapeutic effect in this specific context.